#alphatherapy

Clinical trials are also underway for PSMA-targeted therapy with alpha-emitting radionuclides. Alpha particles are much more energetic and thus cause more localized damage than beta particles. They do not travel as far in tissue, so they tend to have less toxicity. Image shows a patient with metastatic prostate cancer who had excellent response after 2 cycles of actinium-225-PSMA targeted alpha therapy (TAT). Reference: Zacherl et al. J. Nucl. Med. 2021, 62, 669-674.

#TeachingRounds#FOAMed#FOAMRad#Radiology#NuclearMedicine#PETCT